User login
Several studies to be presented at the annual meeting of the American College of Cardiology March 9-11 could change clinical practices. And then there are the mummies.
That’s right, mummies. More than 100 of them. They won’t be lumbering along the hallways of San Francisco’s Moscone Center, but they could tell us whether human ancestors in different parts of the world had atherosclerosis when they died and got mummified.
Following CT scans that showed atherosclerosis was common in a previous study of 52 Egyptian mummies (JACC Cardiovasc. Imaging 2011;4:315-27), investigators have imaged more than 100 mummies of people who lived 3,800 years ago in different cultures around the world. The findings should advance understanding of atherosclerosis in human civilization, ACC.13 Chairman Dr. Miguel A. Quiñones said in a teleconference preview for the press.
Some practice-changing news could come from some of the 22 late-breaking clinical trials and 2,130 abstracts accepted for presentation at the meeting, starting with highly anticipated results from a study of an intervention for atrial fibrillation, said Dr. Quiñones, chair of the department of cardiology in the Methodist Hospital System, Houston, and professor of medicine at Weill Cornell Medical College, New York.
He and a roster of other ACC officials provided these highlights:
• PREVAIL trial: Some of the most anticipated results will come from a trial of elderly patients with atrial fibrillation who were randomized to treatment with a device that allows an electrophysiologist to seal the left atrial appendage (LAA) or to conventional treatment with warfarin to reduce the risk of clots and stroke. For the nearly 1 in 10 U.S. residents aged in their 80s and 90s with atrial fibrillation, a frail physical status puts them at risk of falling, which can cause problematic bleeding if they’re being treated with anticoagulants.
Dr. Quiñones said that he expects the results of the PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients with Atrial Fibrillation Versus Long-term Warfarin Therapy) trial to be "extremely powerful in knowing whether this type of therapy is warranted in a selected group of patients with atrial fibrillation."
• RELAX trial: Treatment for heart failure in patients with a normal ejection fraction hasn’t advanced significantly in 10-15 years, but the RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure) trial could change that, he said. Roughly half of patients with heart failure have a normal ejection fraction, which is increasingly common. The trial studied whether the phosphodiesterase inhibitor sildenafil (Viagra) can improve the relaxation functions of the heart and improve clinical outcomes in these patients who have preserved pumping action but fibroses and stiffness in the heart that produce the symptoms of heart failure.
"Will this new class of agents be a breakthrough in the treatment of a disease that is very important for public health, the cost of health care, and management of diseases?" he asked.
• TACT trial: Preliminary results of TACT (Randomized Comparison of High-dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy), reported at the annual meeting of the American Heart Association last fall, suggested that chelation therapy for atherosclerosis might be beneficial. Investigators will report results of treatment with chelation, high-dose oral vitamins, or placebo, alone or in combination with each other. The results "could be a game changer," Dr. Quiñones said.
• HPS2-THRIVE trial: This study of whether adding niacin and laropiprant to statins is better than statins alone in preventing future myocardial infarction in patients with previous MI or heart disease failed to reach its primary endpoint, Merck announced in late 2012. But the data on more than 25,000 patients provides enough power for potentially useful subgroup analyses, ACC.13 cochair Dr. Christie M. Ballantyne said. The cohort as a whole had low LDL levels at the start of HPS2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events, but U.S. adults tend to have high LDL levels. Subgroup analyses may or may not show a beneficial effect of niacin/laropiprant in some populations, though it will be impossible to say whether any effect is due to the niacin or to laropiprant, which is given to reduce the side effect of flushing caused by niacin, said Dr. Ballantyne, director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart Center, Houston.
• PEITHO trial: Results of the PEITHO (Pulmonary Embolism Thrombolysis) study are of particular interest after tennis star Venus Williams had to drop off the competitive circuit due to pulmonary embolus. The study randomized about 1,000 patients with acute pulmonary embolism in 13 countries to anticoagulation treatment with heparin alone or to heparin plus the clot-busting agent tenecteplase. "The results will help guide therapy and probably will influence the next set of chest guidelines," said ACC.13 cochair Dr. Mark G. Davies, a senior member at the Methodist Hospital Research Institute, Houston.
• Off-pump CABG: A Monday morning session combines three late-breaking trials comparing off-pump and on-pump coronary artery bypass grafting (CABG) that "probably will lead to a very spirited discussion," Dr. Davies said. One of them – the PRAGUE-6 (Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in High-Risk Patients) trial – could be one of the most significant presentations at the meeting, he suggested. Elderly patients were the focus of the GOPCABE (German Off Pump Coronary Artery Bypass Grafting in Elderly Patients) study. In addition, 1-year results will be presented from the CORONARY (Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization) study.
• STREAM trial: Guidelines recommend that patients with acute ST-elevation MI who present to a facility that does not perform percutaneous coronary intervention be transferred to a PCI-capable facility if the procedure can be performed within 2 hours of first medical contact. But rural residents don’t live within a stone’s throw of a catheterization lab, and even urban traffic congestion can block this strategy. The multinational STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial compared this routine-transfer strategy with routine administration of a potent bolus dose of a fibrinolytic agent if PCI cannot be performed within 1 hour, instead of the usual 2-hour window.
"This gets to the question of whether we have embedded an unnecessary and potentially dangerous time delay in a patient’s total ischemic period by stipulating that all patients should be transferred routinely for primary PCI, and whether we’re not taking advantage of this 1-hour window of opportunity, said ACC Vice President Patrick T. O’Gara, director of clinical cardiology at Brigham and Women’s Hospital, Boston. The field of STEMI has not seen a trial of this type for many years, he said.
A list of these and other late-breaking clinical trial presentations can be found on the ACC.13 website.
Dr. Quiñones and Dr. Davies reported having no financial disclosures. Dr. Ballantyne reported receiving speaker and consulting fees and research funds from many pharmaceutical companies. Dr. O’Gara has been on the data and safety monitoring board of Lantheus Medical Imaging.
On Twitter @sherryboschert
Several studies to be presented at the annual meeting of the American College of Cardiology March 9-11 could change clinical practices. And then there are the mummies.
That’s right, mummies. More than 100 of them. They won’t be lumbering along the hallways of San Francisco’s Moscone Center, but they could tell us whether human ancestors in different parts of the world had atherosclerosis when they died and got mummified.
Following CT scans that showed atherosclerosis was common in a previous study of 52 Egyptian mummies (JACC Cardiovasc. Imaging 2011;4:315-27), investigators have imaged more than 100 mummies of people who lived 3,800 years ago in different cultures around the world. The findings should advance understanding of atherosclerosis in human civilization, ACC.13 Chairman Dr. Miguel A. Quiñones said in a teleconference preview for the press.
Some practice-changing news could come from some of the 22 late-breaking clinical trials and 2,130 abstracts accepted for presentation at the meeting, starting with highly anticipated results from a study of an intervention for atrial fibrillation, said Dr. Quiñones, chair of the department of cardiology in the Methodist Hospital System, Houston, and professor of medicine at Weill Cornell Medical College, New York.
He and a roster of other ACC officials provided these highlights:
• PREVAIL trial: Some of the most anticipated results will come from a trial of elderly patients with atrial fibrillation who were randomized to treatment with a device that allows an electrophysiologist to seal the left atrial appendage (LAA) or to conventional treatment with warfarin to reduce the risk of clots and stroke. For the nearly 1 in 10 U.S. residents aged in their 80s and 90s with atrial fibrillation, a frail physical status puts them at risk of falling, which can cause problematic bleeding if they’re being treated with anticoagulants.
Dr. Quiñones said that he expects the results of the PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients with Atrial Fibrillation Versus Long-term Warfarin Therapy) trial to be "extremely powerful in knowing whether this type of therapy is warranted in a selected group of patients with atrial fibrillation."
• RELAX trial: Treatment for heart failure in patients with a normal ejection fraction hasn’t advanced significantly in 10-15 years, but the RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure) trial could change that, he said. Roughly half of patients with heart failure have a normal ejection fraction, which is increasingly common. The trial studied whether the phosphodiesterase inhibitor sildenafil (Viagra) can improve the relaxation functions of the heart and improve clinical outcomes in these patients who have preserved pumping action but fibroses and stiffness in the heart that produce the symptoms of heart failure.
"Will this new class of agents be a breakthrough in the treatment of a disease that is very important for public health, the cost of health care, and management of diseases?" he asked.
• TACT trial: Preliminary results of TACT (Randomized Comparison of High-dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy), reported at the annual meeting of the American Heart Association last fall, suggested that chelation therapy for atherosclerosis might be beneficial. Investigators will report results of treatment with chelation, high-dose oral vitamins, or placebo, alone or in combination with each other. The results "could be a game changer," Dr. Quiñones said.
• HPS2-THRIVE trial: This study of whether adding niacin and laropiprant to statins is better than statins alone in preventing future myocardial infarction in patients with previous MI or heart disease failed to reach its primary endpoint, Merck announced in late 2012. But the data on more than 25,000 patients provides enough power for potentially useful subgroup analyses, ACC.13 cochair Dr. Christie M. Ballantyne said. The cohort as a whole had low LDL levels at the start of HPS2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events, but U.S. adults tend to have high LDL levels. Subgroup analyses may or may not show a beneficial effect of niacin/laropiprant in some populations, though it will be impossible to say whether any effect is due to the niacin or to laropiprant, which is given to reduce the side effect of flushing caused by niacin, said Dr. Ballantyne, director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart Center, Houston.
• PEITHO trial: Results of the PEITHO (Pulmonary Embolism Thrombolysis) study are of particular interest after tennis star Venus Williams had to drop off the competitive circuit due to pulmonary embolus. The study randomized about 1,000 patients with acute pulmonary embolism in 13 countries to anticoagulation treatment with heparin alone or to heparin plus the clot-busting agent tenecteplase. "The results will help guide therapy and probably will influence the next set of chest guidelines," said ACC.13 cochair Dr. Mark G. Davies, a senior member at the Methodist Hospital Research Institute, Houston.
• Off-pump CABG: A Monday morning session combines three late-breaking trials comparing off-pump and on-pump coronary artery bypass grafting (CABG) that "probably will lead to a very spirited discussion," Dr. Davies said. One of them – the PRAGUE-6 (Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in High-Risk Patients) trial – could be one of the most significant presentations at the meeting, he suggested. Elderly patients were the focus of the GOPCABE (German Off Pump Coronary Artery Bypass Grafting in Elderly Patients) study. In addition, 1-year results will be presented from the CORONARY (Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization) study.
• STREAM trial: Guidelines recommend that patients with acute ST-elevation MI who present to a facility that does not perform percutaneous coronary intervention be transferred to a PCI-capable facility if the procedure can be performed within 2 hours of first medical contact. But rural residents don’t live within a stone’s throw of a catheterization lab, and even urban traffic congestion can block this strategy. The multinational STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial compared this routine-transfer strategy with routine administration of a potent bolus dose of a fibrinolytic agent if PCI cannot be performed within 1 hour, instead of the usual 2-hour window.
"This gets to the question of whether we have embedded an unnecessary and potentially dangerous time delay in a patient’s total ischemic period by stipulating that all patients should be transferred routinely for primary PCI, and whether we’re not taking advantage of this 1-hour window of opportunity, said ACC Vice President Patrick T. O’Gara, director of clinical cardiology at Brigham and Women’s Hospital, Boston. The field of STEMI has not seen a trial of this type for many years, he said.
A list of these and other late-breaking clinical trial presentations can be found on the ACC.13 website.
Dr. Quiñones and Dr. Davies reported having no financial disclosures. Dr. Ballantyne reported receiving speaker and consulting fees and research funds from many pharmaceutical companies. Dr. O’Gara has been on the data and safety monitoring board of Lantheus Medical Imaging.
On Twitter @sherryboschert
Several studies to be presented at the annual meeting of the American College of Cardiology March 9-11 could change clinical practices. And then there are the mummies.
That’s right, mummies. More than 100 of them. They won’t be lumbering along the hallways of San Francisco’s Moscone Center, but they could tell us whether human ancestors in different parts of the world had atherosclerosis when they died and got mummified.
Following CT scans that showed atherosclerosis was common in a previous study of 52 Egyptian mummies (JACC Cardiovasc. Imaging 2011;4:315-27), investigators have imaged more than 100 mummies of people who lived 3,800 years ago in different cultures around the world. The findings should advance understanding of atherosclerosis in human civilization, ACC.13 Chairman Dr. Miguel A. Quiñones said in a teleconference preview for the press.
Some practice-changing news could come from some of the 22 late-breaking clinical trials and 2,130 abstracts accepted for presentation at the meeting, starting with highly anticipated results from a study of an intervention for atrial fibrillation, said Dr. Quiñones, chair of the department of cardiology in the Methodist Hospital System, Houston, and professor of medicine at Weill Cornell Medical College, New York.
He and a roster of other ACC officials provided these highlights:
• PREVAIL trial: Some of the most anticipated results will come from a trial of elderly patients with atrial fibrillation who were randomized to treatment with a device that allows an electrophysiologist to seal the left atrial appendage (LAA) or to conventional treatment with warfarin to reduce the risk of clots and stroke. For the nearly 1 in 10 U.S. residents aged in their 80s and 90s with atrial fibrillation, a frail physical status puts them at risk of falling, which can cause problematic bleeding if they’re being treated with anticoagulants.
Dr. Quiñones said that he expects the results of the PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients with Atrial Fibrillation Versus Long-term Warfarin Therapy) trial to be "extremely powerful in knowing whether this type of therapy is warranted in a selected group of patients with atrial fibrillation."
• RELAX trial: Treatment for heart failure in patients with a normal ejection fraction hasn’t advanced significantly in 10-15 years, but the RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure) trial could change that, he said. Roughly half of patients with heart failure have a normal ejection fraction, which is increasingly common. The trial studied whether the phosphodiesterase inhibitor sildenafil (Viagra) can improve the relaxation functions of the heart and improve clinical outcomes in these patients who have preserved pumping action but fibroses and stiffness in the heart that produce the symptoms of heart failure.
"Will this new class of agents be a breakthrough in the treatment of a disease that is very important for public health, the cost of health care, and management of diseases?" he asked.
• TACT trial: Preliminary results of TACT (Randomized Comparison of High-dose Oral Vitamins vs. Placebo in the Trial to Assess Chelation Therapy), reported at the annual meeting of the American Heart Association last fall, suggested that chelation therapy for atherosclerosis might be beneficial. Investigators will report results of treatment with chelation, high-dose oral vitamins, or placebo, alone or in combination with each other. The results "could be a game changer," Dr. Quiñones said.
• HPS2-THRIVE trial: This study of whether adding niacin and laropiprant to statins is better than statins alone in preventing future myocardial infarction in patients with previous MI or heart disease failed to reach its primary endpoint, Merck announced in late 2012. But the data on more than 25,000 patients provides enough power for potentially useful subgroup analyses, ACC.13 cochair Dr. Christie M. Ballantyne said. The cohort as a whole had low LDL levels at the start of HPS2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events, but U.S. adults tend to have high LDL levels. Subgroup analyses may or may not show a beneficial effect of niacin/laropiprant in some populations, though it will be impossible to say whether any effect is due to the niacin or to laropiprant, which is given to reduce the side effect of flushing caused by niacin, said Dr. Ballantyne, director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart Center, Houston.
• PEITHO trial: Results of the PEITHO (Pulmonary Embolism Thrombolysis) study are of particular interest after tennis star Venus Williams had to drop off the competitive circuit due to pulmonary embolus. The study randomized about 1,000 patients with acute pulmonary embolism in 13 countries to anticoagulation treatment with heparin alone or to heparin plus the clot-busting agent tenecteplase. "The results will help guide therapy and probably will influence the next set of chest guidelines," said ACC.13 cochair Dr. Mark G. Davies, a senior member at the Methodist Hospital Research Institute, Houston.
• Off-pump CABG: A Monday morning session combines three late-breaking trials comparing off-pump and on-pump coronary artery bypass grafting (CABG) that "probably will lead to a very spirited discussion," Dr. Davies said. One of them – the PRAGUE-6 (Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery in High-Risk Patients) trial – could be one of the most significant presentations at the meeting, he suggested. Elderly patients were the focus of the GOPCABE (German Off Pump Coronary Artery Bypass Grafting in Elderly Patients) study. In addition, 1-year results will be presented from the CORONARY (Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization) study.
• STREAM trial: Guidelines recommend that patients with acute ST-elevation MI who present to a facility that does not perform percutaneous coronary intervention be transferred to a PCI-capable facility if the procedure can be performed within 2 hours of first medical contact. But rural residents don’t live within a stone’s throw of a catheterization lab, and even urban traffic congestion can block this strategy. The multinational STREAM (Strategic Reperfusion Early After Myocardial Infarction) trial compared this routine-transfer strategy with routine administration of a potent bolus dose of a fibrinolytic agent if PCI cannot be performed within 1 hour, instead of the usual 2-hour window.
"This gets to the question of whether we have embedded an unnecessary and potentially dangerous time delay in a patient’s total ischemic period by stipulating that all patients should be transferred routinely for primary PCI, and whether we’re not taking advantage of this 1-hour window of opportunity, said ACC Vice President Patrick T. O’Gara, director of clinical cardiology at Brigham and Women’s Hospital, Boston. The field of STEMI has not seen a trial of this type for many years, he said.
A list of these and other late-breaking clinical trial presentations can be found on the ACC.13 website.
Dr. Quiñones and Dr. Davies reported having no financial disclosures. Dr. Ballantyne reported receiving speaker and consulting fees and research funds from many pharmaceutical companies. Dr. O’Gara has been on the data and safety monitoring board of Lantheus Medical Imaging.
On Twitter @sherryboschert
FROM A PREVIEW OF ACC 13
